Short-course total neoadjuvant therapy improved five-year survival in STELLAR
Five-year overall survival was 78.1% with short-course total neoadjuvant therapy versus 69.7% with long-course chemoradiotherapy.
Tag
rectal
Immunotherapy-based TNT eliminated nodal disease in ypT0–1 rectal tumours
No positive lymph nodes were found in ypT0–1 tumours after immunotherapy-based TNT, supporting further study of local excision.
Oxaliplatin-based total neoadjuvant therapy improved three-year DFS in high-risk rectal cancer
Doublet total neoadjuvant therapy improved three-year disease-free survival, metastasis-free survival, and pathological complete response compared with conventional chemoradiotherapy.
Multimodal models appear most promising for predicting rectal cancer pathological complete response
No individual clinical, imaging, blood, or molecular marker reliably predicted pathological complete response, while integrated multimodal models showed greater potential.
Planning-CT radiomics improved pretreatment prediction of poor rectal cancer response
Adding CTV radiomics increased internal AUROC from 0.507 to 0.754 for predicting poor response to rectal chemoradiotherapy.
Dose-escalated chemoradiotherapy improved nine-year survival in locally advanced rectal cancer
A 56 Gy simultaneous integrated boost improved nine-year survival and disease control compared with standard 50 Gy chemoradiotherapy.
T1 relaxation mapping identified complete rectal cancer response at six weeks
Quantitative T1 relaxation time distinguished complete from incomplete rectal cancer response six weeks after neoadjuvant treatment with an area under the curve of 0.94.
Higher-BED palliative radiotherapy improved symptoms in rectal cancer
BED >37.5 Gy improved symptomatic control, while 6-month local control remained 46% in frail, elderly, or metastatic rectal cancer.
Dutch survey found wide variation in radiotherapy for unresectable recurrent rectal cancer
Dutch radiation oncologists reported substantial variation in dose, delineation, and follow-up for unresectable locally recurrent rectal cancer.
ESTRO–ASTRO guidance standardises reirradiation for locally recurrent rectal cancer
ESTRO–ASTRO guidance supports selected rectal cancer reirradiation using 30–40 Gy regimens, cumulative dose assessment, inverse planning and daily volumetric imaging.